SCHEMBL508447

SCHEMBL508447

[2H]C([2H])([2H])C([2H])(I)C([2H])([2H])[2H]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1803530 0.75
SCHEMBL30507223 0.67
SCHEMBL13916787 0.67
SCHEMBL12691708 0.64
SCHEMBL508929 0.64
Iodomethane SCHEMBL799995 0.61
Iodoform SCHEMBL2755155 0.61
Iodomethane SCHEMBL87147 0.61
Iodomethane SCHEMBL118500 0.61
Iodomethane SCHEMBL10316995 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042750-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2026-02-12 US disclosed
EP-4688792-A1 KRAS INHIBITORS Eli Lilly and Company (US) 2026-02-11 EP disclosed
US-12479833-B2 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2025-11-25 US disclosed
EP-4593811-A2 DEUTERATED HINOKITIOL DERIVATIVES The Board of Trustees of the University of Illinois (US) 2025-08-06 EP disclosed
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 WO disclosed
WO-2025076235-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-10 WO disclosed
EP-3603674-B1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN SUN PHARMACEUTICAL IND INC (US) 2025-02-26 EP disclosed
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 US disclosed
WO-2024206766-A1 KRAS INHIBITORS ELI LILLY AND COMPANY (US) 2024-10-03 WO disclosed
WO-2024073125-A2 DEUTERATED HINOKITIOL DERIVATIVES THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-04-04 WO disclosed
EP-2418211-A1 Deuterated morphinane compounds Concert Pharmaceuticals Inc. (US) 2012-02-15 EP disclosed
US-20120029007-A1 MORPHINAN COMPOUNDS CONCERT PHARMACEUTICALS INC. 2012-02-02 US disclosed
EP-2397158-A2 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect CONCERT PHARMACEUTICALS, INC. (US) 2011-12-21 EP disclosed
US-20110257214-A1 MORPHINAN COMPOUNDS SUN PHARMACEUTICAL INDUSTRIES, INC. 2011-10-20 US disclosed
EP-2365808-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY Concert Pharmaceuticals Inc. (US) 2011-09-21 EP disclosed
EP-2334678-A1 MORPHINAN COMPOUNDS Concert Pharmaceuticals Inc. (US) 2011-06-22 EP disclosed
WO-2010062692-A1 COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY CONCERT PHARMACEUTICALS INC. (US) 2010-06-03 WO disclosed
WO-2010033801-A1 MORPHINAN COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2010-03-25 WO disclosed
US-20090062561-A1 DEUTERIUM-ENRICHED LATANOPROST PROTIA, LLC (US) 2009-03-05 US disclosed
US-20080171772-A1 e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis ALLERGAN, INC. 2008-07-17 US disclosed